EBS Q2 2017 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$433M

Q2 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$101M+10.4% YoY

Gross Profit

$41M40.3% margin

Operating Income

$9M8.5% margin

Net Income

$5M4.6% margin

EPS (Diluted)

$0.11

QoQ Revenue Growth

-13.8%

Cash Flow

Operating Cash Flow

$54M

Free Cash Flow

$45M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$970M

Total Liabilities

$350M

Stockholders' Equity

$621M

Cash & Equivalents

$316M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$101M	$91M	+10.4%
Gross Profit	$41M	$34M	+19.8%
Operating Income	$9M	-$2M	+517.7%
Net Income	$5M	-$11M	+142.2%